Log in

NASDAQ:CTRVContraVir Pharmaceuticals Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
-0.18 (-8.33 %)
(As of 05/25/2020 11:30 AM ET)
Today's Range
Now: $1.98
50-Day Range
MA: $3.11
52-Week Range
Now: $1.98
Volume508,778 shs
Average Volume432,822 shs
Market Capitalization$1.58 million
P/E RatioN/A
Dividend YieldN/A
ContraVir Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus (HBV) infections. It engages in the development of TXL, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B; and CRV431, a novel drug candidate for the treatment of chronic HBV infection. The company was founded in 2013 and is headquartered in Edison, New Jersey.
Read More
ContraVir Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.60 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:CTRV



Sales & Book Value

Annual SalesN/A
Book Value$0.80 per share


Net Income$-9,450,000.00


Market Cap$1.58 million
Next Earnings DateN/A
OptionableNot Optionable

Receive CTRV News and Ratings via Email

Sign-up to receive the latest news and ratings for CTRV and its competitors with MarketBeat's FREE daily newsletter.

ContraVir Pharmaceuticals (NASDAQ:CTRV) Frequently Asked Questions

How were ContraVir Pharmaceuticals' earnings last quarter?

ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) announced its quarterly earnings data on Friday, May, 13th. The biopharmaceutical company reported ($1.12) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($1.80) by $0.68. View ContraVir Pharmaceuticals' earnings history.

When did ContraVir Pharmaceuticals' stock split? How did ContraVir Pharmaceuticals' stock split work?

ContraVir Pharmaceuticals shares reverse split on the morning of Tuesday, May 29th 2018. The 1-8 reverse split was announced on Thursday, May 24th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 28th 2018. An investor that had 100 shares of ContraVir Pharmaceuticals stock prior to the reverse split would have 13 shares after the split.

Has ContraVir Pharmaceuticals been receiving favorable news coverage?

News stories about CTRV stock have trended somewhat positive this week, InfoTrie Sentiment reports. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. ContraVir Pharmaceuticals earned a media sentiment score of 1.5 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutContraVir Pharmaceuticals.

Who are some of ContraVir Pharmaceuticals' key competitors?

What other stocks do shareholders of ContraVir Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ContraVir Pharmaceuticals investors own include Advaxis (ADXS), Alliqua Biomedical (ALQA), Protalix Biotherapeutics (PLX), Synergy Pharmaceuticals (SGYP), Madrigal Pharmaceuticals (MDGL), Palatin Technologies (PTN), CytRx (CYTR), Sorrento Therapeutics (SRNE), TrovaGene (TROV) and Anavex Life Sciences (AVXL).

Who are ContraVir Pharmaceuticals' key executives?

ContraVir Pharmaceuticals' management team includes the following people:
  • Dr. Robert T. Foster BSc (Pharm), Pharm.D., Ph.D., CEO, Pres, Chief Scientific Officer & Director (Age 61)
  • Dr. John Z. Sullivan-Bolyai, Part-Time Consultant (Age 71)
  • Mr. John T. Cavan, Chief Financial Officer (Age 61)
  • Sharen Pyatetskaya, Director of Investor Relations

What is ContraVir Pharmaceuticals' stock symbol?

ContraVir Pharmaceuticals trades on the NASDAQ under the ticker symbol "CTRV."

What is ContraVir Pharmaceuticals' stock price today?

One share of CTRV stock can currently be purchased for approximately $1.98.

How big of a company is ContraVir Pharmaceuticals?

ContraVir Pharmaceuticals has a market capitalization of $1.58 million. ContraVir Pharmaceuticals employs 14 workers across the globe.

What is ContraVir Pharmaceuticals' official website?

The official website for ContraVir Pharmaceuticals is www.contravir.com.

How can I contact ContraVir Pharmaceuticals?

ContraVir Pharmaceuticals' mailing address is 399 THORNALL STREET FIRST FLOOR, EDISON NJ, 08837. The biopharmaceutical company can be reached via phone at 732-902-4000 or via email at [email protected]

This page was last updated on 5/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.